Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Needham downgraded Biogen Inc BIIB, citing limited catalysts for the company over the next year.Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual without a sharp increase in the near future. The analyst remarked that the physician feedback and expert opinions indicate this slow pace will continue.Leqembi’s third-quarter global in-market sales were approximately $67 million, including U.S. in-market sales of approximately$39 million.Although investors are aware of this, market ...